

NORTH AMERICA INFERTILITY TESTING AND TREATMENT MARKET FORECAST 2018-2026

<https://marketpublishers.com/r/NE356045E42EN.html>

Date: January 2018

Pages: 0

Price: US\$ 1,250.00 (Single User License)

ID: NE356045E42EN

Abstracts

KEY FINDINGS

The North America infertility testing and treatment market collected a net revenue of \$6099.20 million in 2017. Over the forecasted period of 2018-2026, the market is expected to exhibit a CAGR of 6.07%, collecting a net total of \$10326.86 million.

MARKET INSIGHTS

The North American region witnessed about 17% infertility cases due to male factors; while female factors were responsible only in 12% cases. However, rising use of contraceptive drugs is increasing infertility among the North American women. The U.S is the biggest market for infertility testing and treatment in this region, followed by Canada. It is estimated that up to 20% couples in Canada experience infertility to some extent. However, the cost of these infertility treatments varies across both these regions.

COMPETITIVE INSIGHTS

Progyny, Quest Diagnostic, Agilent, Illumina Inc, Andrology Solutions, Thermo Fisher Scientific Inc, Endo Pharmaceuticals, Elucigene, Natera Inc, Esco Micro Pte. Ltd, Ferring Pharmaceuticals, Vitrolife Ab, Integrated Genetics and, Roche are the noted companies in this market.

Contents

1. RESEARCH SCOPE

- 1.1. STUDY GOALS
- 1.2. SCOPE OF THE MARKET STUDY
- 1.3. WHO WILL FIND THIS REPORT USEFUL?
- 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

- 2.1. SOURCES OF DATA
 - 2.1.1. SECONDARY DATA
 - 2.1.2. PRIMARY DATA
- 2.2. TOP DOWN APPROACH
- 2.3. BOTTOM-UP APPROACH
- 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

- 3.1. MARKET SUMMARY
- 3.2. KEY FINDINGS
 - 3.2.1. IVF DOMINATES THE FEMALE TREATMENT MARKET
 - 3.2.2. OXIDATIVE STRESS ANALYSIS IS THE FASTEST GROWING MALE INFERTILITY TESTING MARKET

4. MARKET OVERVIEW

- 4.1. MARKET DEFINITION
- 4.2. MARKET DRIVERS AND IMPACT
 - 4.2.1. RISE IN INFERTILITY AND TREATMENT AWARENESS
 - 4.2.2. MEDICAL TOURISM IN FERTILITY TREATMENTS
 - 4.2.3. SURROGACY LAWS ARE GETTING MORE DEFINED
 - 4.2.4. HEALTHCARE ADVANCES HAVE FINETUNED FERTILITY TREATMENT
 - 4.2.5. INCREASING EFFECTIVENESS OF TREATMENTS
 - 4.2.6. HEALTHIER DONOR EGGS
 - 4.2.7. INTRODUCTION OF NEW TESTING DEVICES
- 4.3. RESTRAINTS AND IMPACT
 - 4.3.1. TREATMENT PROCEDURE OUT OF REACH TO MANY DUE TO COSTS

INVOLVED

4.3.2. COUNTRY-WISE REGULATORY ISSUES

4.4. MARKET OPPORTUNITIES

4.4.1. REDUCING THE COST OF TREATMENT TO MAKE IT MORE ACCESSIBLE

4.4.2. IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS

4.4.3. DIY TESTING INCREASING ACCESS AND REDUCING COST

4.5. MARKET CHALLENGES

4.5.1. INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN

4.5.2. PERILS OF MULTIPLE PREGNANCIES

4.5.3. TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE TO

INFERTILITY TREATMENTS

4.5.3.1. DIET AND SUPPLEMENTS

4.5.3.2. ACUPUNCTURE

4.5.3.3. THERAPY

4.5.3.4. QIGONG

5. INFERTILITY CAUSES

5.1. CAUSES OF MALE INFERTILITY

5.1.1. ABNORMALITY IN THE SPERM

5.1.2. ENVIRONMENTAL FACTORS

5.1.3. POOR HEALTH AND LIFESTYLE

5.2. CAUSES OF FEMALE INFERTILITY

5.2.1. OVULATION DISORDERS

5.2.2. DAMAGE TO FALLOPIAN TUBES

5.3. MORAL QUESTIONS

6. MALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$ MILLION)

6.1. MARKET BY MALE INFERTILITY TESTING

6.1.1. DNA FRAGMENTATION

6.1.2. OXIDATIVE STRESS ANALYSIS

6.1.3. SPERM PENETRATION ASSAY

6.1.4. COMPUTER ASSISTED SEMEN ANALYSIS (CASA)

6.1.5. SPERM AGGLUTINATION

6.1.6. MICROSCOPIC EXAMINATION

6.1.7. OTHERS

6.2. MARKET BY MALE INFERTILITY TREATMENT

6.2.1. VASOVASOSTOMY AND VASOEPIDIDYMOSTOMY (VASECTOMY REVERSAL)

6.2.2. SPERM RETRIEVAL TREATMENT

6.2.3. MICROSURGICAL SPERM ASPIRATION (MESA)

6.2.4. TESTICULAR SPERM EXTRACTION (TESE)

6.2.5. VARICOCELE REPAIRS

6.2.6. ASSISTED REPRODUCTIVE TECHNIQUES (ART)

6.2.7. INTRAUTERINE INSEMINATION (IUI)

6.2.8. IN VITRO FERTILIZATION (IVF)

6.2.9. INTRACYTOPLASMIC SPERM INJECTION (ICSI)

7. FEMALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$ MILLION)

7.1. MARKET BY FEMALE INFERTILITY TESTING

7.1.1. OVULATION TESTING

7.1.2. HYSTEOSALPINGOGRAPHY

7.1.3. LAPAROSCOPY

7.1.4. TRANSVAGINAL ULTRASOUND

7.1.5. OVARIAN RESERVE TESTING

7.1.6. HORMONAL LEVEL TESTING

7.1.7. OTHERS (GENETIC TESTING)

7.2. MARKET BY FEMALE INFERTILITY TREATMENT

7.2.1. IN VITRO FERTILIZATION

7.2.2. INTRAUTERINE INSEMINATION (IUI)

7.2.3. DRUG AND HORMONE THERAPIES

8. NORTH AMERICA INFERTILITY TESTING AND TREATMENT MARKET BY END-USERS 2018-2026 (\$ MILLION)

8.1. FERTILITY AND SURGICAL CENTERS

8.2. HOSPITALS AND RESEARCH LABORATORIES

8.3. CRYOBANKS

9. KEY ANALYTICS

9.1. PORTERS 5 FORCE MODEL

9.1.1. THREAT OF NEW ENTRANTS

9.1.2. THREAT OF SUBSTITUTE PRODUCTS

- 9.1.3. BARGAINING POWER OF BUYERS
- 9.1.4. BARGAINING POWER OF SUPPLIERS
- 9.1.5. INTENSITY OF COMPETITIVE RIVALRY
- 9.2. VALUE CHAIN ANALYSIS
 - 9.2.1. RAW MATERIAL PROCUREMENT
 - 9.2.2. MANUFACTURING
 - 9.2.3. SUPPLY LOGISTICS
 - 9.2.4. DISTRIBUTION CHANNELS
 - 9.2.5. END USERS
- 9.3. KEY BUYING CRITERIA
 - 9.3.1. TREATMENT OPTIONS
 - 9.3.2. QUALITY OF MEDICAL PROCEDURES
 - 9.3.3. PRICE OF TREATMENTS
 - 9.3.4. SHIFT TOWARDS MEDICAL TOURISM
 - 9.3.5. REIMBURSEMENT
- 9.4. REGULATORY FRAMEWORK
- 9.5. KEY TRENDS
 - 9.5.1. MALE INFERTILITY TREATMENT SEGMENT IS RISING
 - 9.5.2. FERTILITY TOURISM- AN IMPORTANT TREND
 - 9.5.3. UPPER MIDDLE INCOME GROUP IS THE KEY TARGET
 - 9.5.4. REGULATORY ENVIRONMENT KEY MARKET ENABLER
 - 9.5.5. MORE COUPLES OPTING FOR SURROGACY
 - 9.5.6. TECHNOLOGY ENABLING THE SUCCESS OF FERTILITY TREATMENTS
- 9.6. VENDOR LANDSCAPE
- 9.7. OPPORTUNITY MATRIX

10. KEY ANALYTICS – TESTING MARKET

- 10.1. PORTERS 5 FORCE ANALYSIS
 - 10.1.1. THREAT OF NEW ENTRANTS
 - 10.1.2. THREAT OF SUBSTITUTE PRODUCTS
 - 10.1.3. BARGAINING POWER OF BUYERS
 - 10.1.4. BARGAINING POWER OF SUPPLIERS
 - 10.1.5. INTENSITY OF COMPETITIVE RIVALRY
- 10.2. KEY BUYING CRITERIA
- 10.3. VENDOR LANDSCAPE
- 10.4. OPPORTUNITY MATRIX

11. NORTH AMERICA INFERTILITY TESTING AND TREATMENT MARKET

COUNTRY ANALYSIS 2018-2026 (\$ MILLION)

- 11.1. US
- 11.2. CANADA

12. COMPETITIVE ANALYSIS

- 12.1. ANDROLOGY SOLUTIONS
 - 12.1.1. OVERVIEW
 - 12.1.2. PRODUCT PORTFOLIO
 - 12.1.3. SCOT ANALYSIS
- 12.2. ENDO PHARMACEUTICALS
 - 12.2.1. OVERVIEW
 - 12.2.2. PRODUCT PORTFOLIO
 - 12.2.3. STRATEGIC MOVES
 - 12.2.4. SCOT ANALYSIS
- 12.3. PROGYNY
 - 12.3.1. OVERVIEW
 - 12.3.2. PRODUCT PORTFOLIO
 - 12.3.3. STRATEGIC MOVES
 - 12.3.4. SCOT ANALYSIS
- 12.4. FERRING PHARMACEUTICALS
 - 12.4.1. OVERVIEW
 - 12.4.2. PRODUCT PORTFOLIO
 - 12.4.3. STRATEGIC MOVES
 - 12.4.4. SCOT ANALYSIS
- 12.5. GENE A
 - 12.5.1. OVERVIEW
 - 12.5.2. PRODUCT PORTFOLIO
 - 12.5.3. STRATEGIC MOVES
 - 12.5.4. SCOT ANALYSIS
- 12.6. HALOTECH DNA
 - 12.6.1. OVERVIEW
 - 12.6.2. PRODUCT PORTFOLIO
 - 12.6.3. STRATEGIC MOVES
 - 12.6.4. SCOT ANALYSIS
- 12.7. IRVINE SCIENTIFIC
 - 12.7.1. OVERVIEW
 - 12.7.2. PRODUCT PORTFOLIO

- 12.7.3. STRATEGIC MOVES
- 12.7.4. SCOT ANALYSIS
- 12.8. MERCK
 - 12.8.1. OVERVIEW
 - 12.8.2. PRODUCT PORTFOLIO
 - 12.8.3. STRATEGIC MOVES
 - 12.8.4. SCOT ANALYSIS
- 12.9. ORIGIO
 - 12.9.1. OVERVIEW
 - 12.9.2. PRODUCT PORTFOLIO
 - 12.9.3. STRATEGIC MOVES
 - 12.9.4. SCOT ANALYSIS
- 12.10. OVASCIENCE
 - 12.10.1. OVERVIEW
 - 12.10.2. PRODUCT PORTFOLIO
 - 12.10.3. STRATEGIC MOVES
 - 12.10.4. SCOT ANALYSIS
- 12.11. VITROLIFE AB
 - 12.11.1. OVERVIEW
 - 12.11.2. PRODUCT PORTFOLIO
 - 12.11.3. STRATEGIC MOVES
 - 12.11.4. SCOT ANALYSIS
- 12.12. THERMO FISHER SCIENTIFIC INC
 - 12.12.1. OVERVIEW
 - 12.12.2. PRODUCT PORTFOLIO
 - 12.12.3. STRATEGIC MOVES
 - 12.12.4. SCOT ANALYSIS
- 12.13. THE COOPER COMPANIES, INC
 - 12.13.1. OVERVIEW
 - 12.13.2. PRODUCT PORTFOLIO
 - 12.13.3. STRATEGIC MOVES
 - 12.13.4. SCOT ANALYSIS
- 12.14. QUEST DIAGNOSTIC
 - 12.14.1. OVERVIEW
 - 12.14.2. PRODUCT PORTFOLIO
 - 12.14.3. SCOT ANALYSIS
 - 12.14.4. STRATEGIC MOVES
- 12.15. ESCO MICRO PTE. LTD.
 - 12.15.1. OVERVIEW

- 12.15.2. PRODUCT PORTFOLIO
- 12.15.3. STRATEGIC MOVES
- 12.15.4. SCOT ANALYSIS
- 12.16. ELUCIGENE
 - 12.16.1. OVERVIEW
 - 12.16.2. PRODUCT PORTFOLIO
 - 12.16.3. SCOT ANALYSIS
 - 12.16.4. STRATEGIC INITIATIVE
- 12.17. ALERE
 - 12.17.1. OVERVIEW
 - 12.17.2. PRODUCT PORTFOLIO
 - 12.17.3. SCOT ANALYSIS
 - 12.17.4. STRATEGIC INITIATIVE
- 12.18. CELMATRIX
 - 12.18.1. OVERVIEW
 - 12.18.2. PRODUCT PORTFOLIO
 - 12.18.3. SCOT ANALYSIS
 - 12.18.4. STRATEGIC INITIATIVE
- 12.19. VERITAS GENETICS
 - 12.19.1. OVERVIEW
 - 12.19.2. PRODUCT PORTFOLIO
 - 12.19.3. SCOT ANALYSIS
 - 12.19.4. STRATEGIC INITIATIVE
- 12.20. CLARITAS GENOMICS
 - 12.20.1. OVERVIEW
 - 12.20.2. PRODUCT PORTFOLIO
 - 12.20.3. SCOT ANALYSIS
 - 12.20.4. STRATEGIC INITIATIVE
- 12.21. ROCHE
 - 12.21.1. OVERVIEW
 - 12.21.2. PRODUCT PORTFOLIO
 - 12.21.3. SCOT ANALYSIS
 - 12.21.4. STRATEGIC INITIATIVE
- 12.22. LABCORP
 - 12.22.1. OVERVIEW
 - 12.22.2. PRODUCT PORTFOLIO
 - 12.22.3. SCOT ANALYSIS
 - 12.22.4. STRATEGIC INITIATIVE
- 12.23. AGILENT

- 12.23.1. OVERVIEW
- 12.23.2. PRODUCT PORTFOLIO
- 12.23.3. SCOT ANALYSIS
- 12.23.4. STRATEGIC INITIATIVE
- 12.24. INTEGRATED GENETICS
 - 12.24.1. OVERVIEW
 - 12.24.2. PRODUCT PORTFOLIO
 - 12.24.3. SCOT ANALYSIS
- 12.25. PHOSPHORUS DIAGNOSTICS
 - 12.25.1. OVERVIEW
 - 12.25.2. PRODUCT PORTFOLIO
 - 12.25.3. SCOT ANALYSIS
 - 12.25.4. STRATEGIC INITIATIVE
- 12.26. CENTOGENE
 - 12.26.1. OVERVIEW
 - 12.26.2. PRODUCT PORTFOLIO
 - 12.26.3. SCOT ANALYSIS
 - 12.26.4. STRATEGIC INITIATIVE
- 12.27. NATERA INC
 - 12.27.1. OVERVIEW
 - 12.27.2. PRODUCT PORTFOLIO
 - 12.27.3. SCOT ANALYSIS
 - 12.27.4. STRATEGIC INITIATIVE
- 12.28. ILLUMINA INC
 - 12.28.1. OVERVIEW
 - 12.28.2. PRODUCT PORTFOLIO
 - 12.28.3. SCOT ANALYSIS
 - 12.28.4. STRATEGIC INITIATIVE

COMPANIES MENTIONED

1. ANDROLOGY SOLUTIONS
2. ENDO PHARMACEUTICALS
3. PROGYNY
4. FERRING PHARMACEUTICALS
5. GENE A
6. HALOTECH DNA
7. IRVINE SCIENTIFIC

8. MERCK
9. ORIGIO
10. OVASCIENCE
11. VITROLIFE AB
12. THERMO FISHER SCIENTIFIC INC
13. THE COOPER COMPANIES, INC
14. QUEST DIAGNOSTIC
15. ESCO MICRO PTE. LTD.
16. ELUCIGENE
17. ALERE
18. CELMATRIX
19. VERITAS GENETICS
20. CLARITAS GENOMICS
21. ROCHE
22. LABCORP
23. AGILENT
24. INTEGRATED GENETICS
25. PHOSPHORUS DIAGNOSTICS
26. CENTOGENE
27. NATERA INC
28. ILLUMINA INC

I would like to order

Product name: NORTH AMERICA INFERTILITY TESTING AND TREATMENT MARKET FORECAST
2018-2026

Product link: <https://marketpublishers.com/r/NE356045E42EN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer
Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click
button on product page <https://marketpublishers.com/r/NE356045E42EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form
below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms
& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970

